GlassScriptPhysician profile
Michelle D Corrales
NPI 1174736193
$3,056.48
in general payments reported to CMS, 2019-2025
30 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $87.32 · 2021: $243 · 2022: $343 · 2023: $609 · 2024: $815 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.92 |
| Education | $110.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $843.78 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $502.20 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $274.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $208.67 | 2023-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $138.23 | 2024-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $134.09 | 2021-2025 | Zoryve |
| Pfizer INC. | $100.95 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.37 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $82.86 | 2022-2025 | |
| Medtronic, INC. | $81.56 | 2023 | Corevalve Evolut R |
| Exact Sciences Corporation | $72.58 | 2024-2025 | Cologuard Collection Kit |
| Procept Biorobotics Corporation | $70.21 | 2025 | |
| Xeris Pharmaceuticals, INC. | $56.82 | 2025 | Recorlev |
| Idorsia Pharmaceuticals US INC | $42.72 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $41.51 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $32.94 | 2023 | Rexulti |
| Corcept Therapeutics | $32.16 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $30.45 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.92 | 2024 | Voquezna |
| Heartflow, INC. | $23.46 | 2023 | Ffrct |
| Smith+Nephew, INC. | $20.62 | 2020 | |
| Axonics, INC. | $19.32 | 2021 | |
| Currax Pharmaceuticals LLC | $16.55 | 2021 | |
| Merck Sharp & Dohme LLC | $15.96 | 2022 | |
| Lundbeck LLC | $15.88 | 2023 | Rexulti |
| Averitas Pharma INC. | $14.88 | 2025 | Qutenza |
| Daiichi Sankyo INC. | $14.66 | 2022 | |
| Glaxosmithkline, LLC. | $14.29 | 2023 | Arexvy |
| Ibsa Pharma INC. | $14.22 | 2022 | |
| Abbvie INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Corrales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.